DuranteC, HaddyN, BaudinE, et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocr Metab, 2006; 91(8):2892–2899; doi: 10.1210/Jc.2005-2838
2.
BroseMS, NuttingCM, JarzabB, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet, 2014; 384(9940):319–328; doi: 10.1016/S0140-6736(14)60421-9
3.
SchlumbergerM, TaharaM, WirthLJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New Engl J Med, 2015; 372(7):621–630; doi: 10.1056/Nejmoa1406470
4.
LiuDX, HuSY, HouP, et al.Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res, 2007; 13(4):1341–1349; doi: 10.1158/1078-0432.Ccr-06-1753
5.
HoAL, GrewalRK, LeboeufR, et al.Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New Engl J Med, 2013; 368(7):623–632; doi: 10.1056/Nejmoa1209288
6.
BrownSR, HallA, BuckleyHL, et al.Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): Protocol for a multicentre UK single arm phase II trial. BMC Cancer, 2019; 19(1):582; doi: 10.1186/s12885-019-5541-4
7.
GregoryRA, MurrayI, GearJ, et al.Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol, 2019; 64(24):245013; doi: 10.1088/1361-6560/ab5b6c
8.
EisenhauerEA, TherasseP, BogaertsJ, et al.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer (1990), 2008; 45(2):228–247; doi: 10.1016/j.ejca.2008.10.026
9.
CaseLD, MorganTM. Design of Phase II cancer trials evaluating survival probabilities. BMC Med Res Methodol, 2003; 3(1):6; doi: 10.1186/1471-2288-3-6
10.
RothenbergSM, McFaddenDG, PalmerEL, et al.Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res, 2015; 21:1028–1035.
11.
TrapoggeJ, AbreuC, YusufS, et al.The role of pre-therapy quantitative imaging and dosimetry in radioiodine therapy for advanced thyroid cancer. J Nucl Med, 2023:jnumed.122.264913; doi: 10.2967/jnumed.122.264913
